|
Feb 14
|
Lixte Biotechnology announces closing of $1.05M registered direct offering
|
|
Feb 13
|
LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Feb 11
|
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Feb 10
|
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
|
|
Aug 15
|
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
|
|
Aug 15
|
Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
|
|
Jun 14
|
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
|
|
Jun 14
|
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
|
|
May 20
|
LIXTE Biotechnology Holdings Provides Update on Recent Activities
|
|
Jul 18
|
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
|
|
Jul 17
|
Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
|